TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-22
DOI
10.3389/fimmu.2021.699895
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
- (2021) Zhouhong Ge et al. Cellular and Molecular Gastroenterology and Hepatology
- TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer
- (2020) Danhua Xu et al. IMMUNOBIOLOGY
- Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma
- (2020) Ailin Lepletier et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
- (2020) David Kung-Chun Chiu et al. GASTROENTEROLOGY
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming genetically-based resistance mechanisms to PD-1 blockade
- (2020) Davis Y. Torrejon et al. Cancer Discovery
- CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
- (2020) Hyung-seung Jin et al. Cancer Immunology Research
- Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
- (2020) Liliana E. Lucca et al. Neurology-Neuroimmunology & Neuroinflammation
- TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma
- (2020) Zhi-Zhang Yang et al. CLINICAL CANCER RESEARCH
- Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
- (2020) Ester Lozano et al. CLINICAL CANCER RESEARCH
- IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
- (2020) Joe-Marc Chauvin et al. CLINICAL CANCER RESEARCH
- Transcriptome profiling identifies TIGIT as a marker of T cell exhaustion in liver cancer
- (2020) Dmitrij Ostroumov et al. HEPATOLOGY
- Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
- (2020) Adi Reches et al. Journal for ImmunoTherapy of Cancer
- 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
- (2020) M-J. Ahn et al. ANNALS OF ONCOLOGY
- 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
- (2020) J. Niu et al. ANNALS OF ONCOLOGY
- Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
- (2020) Marianne Weulersse et al. IMMUNITY
- PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
- (2020) Catherine L. Tan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
- (2019) Fernando Souza-Fonseca-Guimaraes et al. TRENDS IN IMMUNOLOGY
- PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
- (2019) Sarah Whelan et al. Cancer Immunology Research
- Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
- (2019) Benjamin Murter et al. Cancer Immunology Research
- TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma
- (2019) Sarah E Josefsson et al. Cancer Immunology Research
- DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
- (2019) Beatriz Sanchez-Correa et al. Cancers
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma
- (2019) Xiaoli Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
- (2019) Jiaqiang Ma et al. Journal for ImmunoTherapy of Cancer
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
- (2018) Xian-Yang Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
- (2018) Karen O. Dixon et al. JOURNAL OF IMMUNOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- Emerging strategies for combination checkpoint modulators in cancer immunotherapy
- (2018) Aleksandra Popovic et al. JOURNAL OF CLINICAL INVESTIGATION
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma
- (2018) Haoyu Sun et al. HEPATOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
- (2016) Marco De Simone et al. IMMUNITY
- Identification of CD112R as a novel checkpoint for human T cells
- (2016) Yuwen Zhu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
- (2016) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- “Natural Regulators”: NK Cells as Modulators of T Cell Immunity
- (2016) Iona S. Schuster et al. Frontiers in Immunology
- Recognition and Regulation of T Cells by NK Cells
- (2016) Katharina Pallmer et al. Frontiers in Immunology
- TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals
- (2015) Feng Wang et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
- (2015) Christopher A. Fuhrman et al. JOURNAL OF IMMUNOLOGY
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+T Cells
- (2015) Hyo Jin Park et al. JOURNAL OF IMMUNOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
- (2015) Valentina Bevelacqua et al. Oncotarget
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
- (2014) Kristen E. Pauken et al. CANCER CELL
- Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
- (2014) Nicole Joller et al. IMMUNITY
- T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
- (2014) Man Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
- (2014) M. C. B. Tan et al. JOURNAL OF IMMUNOLOGY
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- CFL1 and Arp3 are Biomarkers for Metastasis and Poor Prognosis of Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of Gallbladder
- (2013) Zhu-Lin Yang et al. CANCER INVESTIGATION
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Vstm3 is a member of the CD28 family and an important modulator of T-cell function
- (2011) Steven D. Levin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
- (2011) Beatriz Sanchez-Correa et al. IMMUNOLOGY AND CELL BIOLOGY
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma
- (2010) Reiko Nakai et al. CANCER SCIENCE
- Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines
- (2009) Javier G. Casado et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
- (2009) Kent S. Boles et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV
- (2009) Debora Franceschini et al. JOURNAL OF CLINICAL INVESTIGATION
- Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
- (2009) M. Carlsten et al. JOURNAL OF IMMUNOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now